BioSpace News Archive

Agilent Technologies Inc. (NYSE: A) today announced new LC/MS and GC/MS quadrupole mass spectrometers which will be on show at the 70th ASMS Conference on Mass Spectrometry and Allied Topics being held June 5 - 9, 2022 in Minneapolis, Minnesota.

myCare-004 Study Finds Cellworks Personalized Therapy Biosimulation Provides Superior OS, DFS and TRG Predictions for GEA Patients.

myCare-024-04 Study Finds Cellworks Personalized Biosimulation Provides Superior OS and PFS Predictions for GBM Patients Beyond Standard Clinical Factors.

Up-round financing follows a previously unannounced $600 million Series C Financing completed in August 2021.

SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human donors, today announced the appointment of Alexandra Kropotova, M.D., as Chief Medical Officer (CMO).

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced that it has entered into definitive agreements with a single healthcare-focused institutional investor and certain of the Company’s executives, for the purchase and sale of 8,850,000 shares of its common stock.

Company Expects to Achieve Approximately $100 Million in Cost Savings Over the Next 12 Months* While Continuing to Invest in European Launches and Global Expansion.

Consistent with approved antibody inhibitors of PD-L1, CCX559 demonstrates immunomodulatory activity in first cycle of treatment.

Nanalysis Scientific Corp. announces it will be attending the following upcoming conferences.

Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced that the American Journal of Hematology has accepted for publication the final study results and analysis of the pivotal phase 3 clinical trial of treosulfan conducted by medac, a strategic partner of Medexus.